serotonin2A
Bluelighter
- Joined
- Sep 13, 2014
- Messages
- 1,354
Yeah, this is exactly what we need all over the world, together with some completely new drugs like sigma & kappa antagonists, 5-HT2A inverse agonists and subtype-selective serotonergics in general, more selective glutamate modulators etc ... (not to forget about the real possibility of opioid agonists that lack tolerance development & respiratory depression) !!
Why are there so few creative, innovative people at the crucial positions!?
All of the drugs you listed have been through clinical trials and they all failed as antipsychotics. There are so many novel drugs that have failed -- it's amazing and quite disappointing. mGlu2 agonists, 5-HT2A antagonists, glycine, D-cycloserine, pomaglumetad, bitopertin, volinaserin, ACP-104, AM-831... All of these drugs, and many more, were found to be ineffective in recent clinical trials. I really don't get why you think there are not creative, innovative people working on this problem? Unfortunately, it turns out to be extremely difficult to discover new classes of antipsychotics.
The only exception has been pimavanserin for Parkinson's psychosis. But that is a special case, because the visual hallucinations in those patients occur due to 5-HT2A supersensitivity. But again, it shows people have been trying to find new drugs.